Benzinga | Aug 4, 2021 05:02PM EDT

Supernus Pharmaceuticals Q2 EPS $0.43 Beats $0.20 Estimate, Sales $141.30M Beat $134.87M Estimate

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.20 by 115 percent. This is a 33.85 percent decrease over earnings of $0.65 per share from the same period last year. The company reported quarterly sales of $141.30 million which beat the analyst consensus estimate of $134.87 million by 4.77 percent. This is a 11.50 percent increase over sales of $126.73 million the same period last year.